Tags

Type your tag names separated by a space and hit enter

Interplay between methylenetetrahydrofolate reductase gene polymorphism 677C-->T and serum folate levels in determining hyperhomocysteinemia in heart transplant recipients.
J Heart Lung Transplant 2001; 20(12):1245-51JH

Abstract

BACKGROUND

Homocysteine metabolism is often impaired in heart transplant recipients, and increased total homocysteine plasma levels may constitute a risk factor for the development of heart allograft vascular disease. Although 677C-->T transition in methylenetetrahydrofolate reductase (MTHFR) is associated with increased homocysteine levels in the general population, it is unclear whether MTHFR polymorphism influences homocysteine metabolism after heart transplant.

METHODS

Homocysteine, serum folate, renal function, concentrations of cyclosporine and its metabolites, and MTHFR genotype were determined in 57 heart transplant recipients (age, 55 +/- 11 yr; 21% women; time from transplant, 48 +/- 42 months).

RESULTS

Forty nine percent of the study population presented with hyperhomocysteinemia. Homocysteine was 17.1 +/- 5.9 micromol/liter, 19.4 +/- 4.9 micromol/liter, and 26.3 +/- 14.2 micromol/liter for genotypes CC, CT, and TT, respectively (p = 0.028, Kruskal-Wallis test). At multivariate analysis, MTHFR genotype was independently associated with homocysteine (p = 0.005). When the study population was divided into 2 groups accordingly to serum folate levels (above/below the median value of 6.1 ng/ml), MTHFR genotype remained a significant predictor of homocysteine only in patients with low serum folate (p = 0.048).

CONCLUSIONS

This study demonstrates that hyperhomocysteinemia is frequent in heart transplant recipients and that the 677C-->T transition in the MTHFR gene independently and unfavorably influences homocysteine metabolism in this group of patients. Adequate folate intake may overcome genetic predisposition to hyperhomocysteinemia.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11744407

Citation

Potena, L, et al. "Interplay Between Methylenetetrahydrofolate Reductase Gene Polymorphism 677C-->T and Serum Folate Levels in Determining Hyperhomocysteinemia in Heart Transplant Recipients." The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation, vol. 20, no. 12, 2001, pp. 1245-51.
Potena L, Grigioni F, Viggiani M, et al. Interplay between methylenetetrahydrofolate reductase gene polymorphism 677C-->T and serum folate levels in determining hyperhomocysteinemia in heart transplant recipients. J Heart Lung Transplant. 2001;20(12):1245-51.
Potena, L., Grigioni, F., Viggiani, M., Magnani, G., Sorbello, S., Falchetti, E., ... Branzi, A. (2001). Interplay between methylenetetrahydrofolate reductase gene polymorphism 677C-->T and serum folate levels in determining hyperhomocysteinemia in heart transplant recipients. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation, 20(12), pp. 1245-51.
Potena L, et al. Interplay Between Methylenetetrahydrofolate Reductase Gene Polymorphism 677C-->T and Serum Folate Levels in Determining Hyperhomocysteinemia in Heart Transplant Recipients. J Heart Lung Transplant. 2001;20(12):1245-51. PubMed PMID: 11744407.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Interplay between methylenetetrahydrofolate reductase gene polymorphism 677C-->T and serum folate levels in determining hyperhomocysteinemia in heart transplant recipients. AU - Potena,L, AU - Grigioni,F, AU - Viggiani,M, AU - Magnani,G, AU - Sorbello,S, AU - Falchetti,E, AU - Sassi,S, AU - Mantovani,V, AU - Bacchi-Reggiani,L, AU - Magelli,C, AU - Branzi,A, PY - 2001/12/18/pubmed PY - 2002/3/19/medline PY - 2001/12/18/entrez SP - 1245 EP - 51 JF - The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation JO - J. Heart Lung Transplant. VL - 20 IS - 12 N2 - BACKGROUND: Homocysteine metabolism is often impaired in heart transplant recipients, and increased total homocysteine plasma levels may constitute a risk factor for the development of heart allograft vascular disease. Although 677C-->T transition in methylenetetrahydrofolate reductase (MTHFR) is associated with increased homocysteine levels in the general population, it is unclear whether MTHFR polymorphism influences homocysteine metabolism after heart transplant. METHODS: Homocysteine, serum folate, renal function, concentrations of cyclosporine and its metabolites, and MTHFR genotype were determined in 57 heart transplant recipients (age, 55 +/- 11 yr; 21% women; time from transplant, 48 +/- 42 months). RESULTS: Forty nine percent of the study population presented with hyperhomocysteinemia. Homocysteine was 17.1 +/- 5.9 micromol/liter, 19.4 +/- 4.9 micromol/liter, and 26.3 +/- 14.2 micromol/liter for genotypes CC, CT, and TT, respectively (p = 0.028, Kruskal-Wallis test). At multivariate analysis, MTHFR genotype was independently associated with homocysteine (p = 0.005). When the study population was divided into 2 groups accordingly to serum folate levels (above/below the median value of 6.1 ng/ml), MTHFR genotype remained a significant predictor of homocysteine only in patients with low serum folate (p = 0.048). CONCLUSIONS: This study demonstrates that hyperhomocysteinemia is frequent in heart transplant recipients and that the 677C-->T transition in the MTHFR gene independently and unfavorably influences homocysteine metabolism in this group of patients. Adequate folate intake may overcome genetic predisposition to hyperhomocysteinemia. SN - 1053-2498 UR - https://www.unboundmedicine.com/medline/citation/11744407/Interplay_between_methylenetetrahydrofolate_reductase_gene_polymorphism_677C__>T_and_serum_folate_levels_in_determining_hyperhomocysteinemia_in_heart_transplant_recipients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1053249801003503 DB - PRIME DP - Unbound Medicine ER -